AU2018274184B2 - Novel PSMA-binding agents and uses thereof - Google Patents
Novel PSMA-binding agents and uses thereof Download PDFInfo
- Publication number
- AU2018274184B2 AU2018274184B2 AU2018274184A AU2018274184A AU2018274184B2 AU 2018274184 B2 AU2018274184 B2 AU 2018274184B2 AU 2018274184 A AU2018274184 A AU 2018274184A AU 2018274184 A AU2018274184 A AU 2018274184A AU 2018274184 B2 AU2018274184 B2 AU 2018274184B2
- Authority
- AU
- Australia
- Prior art keywords
- psma
- alb
- tumor
- compound
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/52—Devices using data or image processing specially adapted for radiation diagnosis
- A61B6/5211—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data
- A61B6/5229—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data combining image data of a patient, e.g. combining a functional image with an anatomical image
- A61B6/5235—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data combining image data of a patient, e.g. combining a functional image with an anatomical image combining images from the same or different ionising radiation imaging techniques, e.g. PET and CT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0495—Pretargeting
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Medical Informatics (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Radiology & Medical Imaging (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Computer Vision & Pattern Recognition (AREA)
- High Energy & Nuclear Physics (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17000891.6 | 2017-05-24 | ||
| EP17000891 | 2017-05-24 | ||
| AUPCT/EP2017/000717 | 2017-06-20 | ||
| PCT/EP2017/000717 WO2018233798A1 (en) | 2017-06-20 | 2017-06-20 | Novel psma-binding agents and uses thereof |
| PCT/EP2018/063734 WO2018215627A1 (en) | 2017-05-24 | 2018-05-24 | Novel psma-binding agents and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2018274184A1 AU2018274184A1 (en) | 2019-11-07 |
| AU2018274184B2 true AU2018274184B2 (en) | 2024-06-13 |
Family
ID=62200468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018274184A Active AU2018274184B2 (en) | 2017-05-24 | 2018-05-24 | Novel PSMA-binding agents and uses thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11629201B2 (enExample) |
| EP (1) | EP3630204A1 (enExample) |
| JP (1) | JP7340459B2 (enExample) |
| KR (1) | KR102843240B1 (enExample) |
| CN (1) | CN110740757B (enExample) |
| AU (1) | AU2018274184B2 (enExample) |
| CA (1) | CA3060143A1 (enExample) |
| WO (1) | WO2018215627A1 (enExample) |
| ZA (1) | ZA201906832B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102884167B1 (ko) * | 2017-10-22 | 2025-11-12 | 프로빈셜 헬스 서비시즈 오쏘리티 | 전립선 특이적 막 항원-발현 암의 진단 또는 치료를 위한 신규한 라디오메탈-결합 화합물 |
| US12228480B2 (en) * | 2018-11-30 | 2025-02-18 | Revvity Health Sciences, Inc. | Biological sample preparation using electric fields |
| WO2020150617A2 (en) * | 2019-01-17 | 2020-07-23 | Case Western Reserve University | Peptide pet/spect probes specific to oncoproteins in tumor extracellula matrix |
| US12472272B2 (en) | 2019-04-17 | 2025-11-18 | Provincial Health Services Authority | Radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen- expressing cancer |
| US20220313600A1 (en) * | 2019-05-24 | 2022-10-06 | Clarity Pharmaceuticals Limited | Formulations of psma imaging agents |
| CN119431260A (zh) | 2019-06-21 | 2025-02-14 | 省卫生服务机构 | 靶向前列腺特异性膜抗原的放射性标记化合物 |
| TWI803688B (zh) * | 2019-08-26 | 2023-06-01 | 行政院原子能委員會核能研究所 | 一種psma靶向放射診療藥物備製方法 |
| KR102269315B1 (ko) * | 2019-10-24 | 2021-06-24 | 서울대학교산학협력단 | 전립선 암의 영상 또는 치료를 위한 동위원소 표지 화합물 |
| CN113350531A (zh) * | 2020-03-02 | 2021-09-07 | 上海核力星医药科技有限公司 | 前列腺特异性膜抗原结合配体偶联物及其应用 |
| WO2022096103A1 (en) | 2020-11-05 | 2022-05-12 | ITM Isotopen Technologien München AG | Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer |
| WO2022111800A1 (en) | 2020-11-25 | 2022-06-02 | Itm Solucin Gmbh | Stable formulations for radionuclide complexes |
| KR20230154183A (ko) * | 2021-03-04 | 2023-11-07 | 니혼 메디피직스 가부시키가이샤 | 화합물 및 방사성 표지 화합물 |
| MX2023013836A (es) * | 2021-05-21 | 2024-01-11 | Northstar Medical Tech Llc | Radiofármaco dirigido al receptor del activador de plasminógeno uroquinasa. |
| US20250319194A1 (en) * | 2021-09-03 | 2025-10-16 | Bivision Pharmaceuticals, Inc. | Peptide-urea derivative, pharmaceutical composition containing same and application thereof |
| EP4431503A1 (en) * | 2021-11-10 | 2024-09-18 | Suzhou Ruihe Medicine Technology Co., Ltd | Ligand compound targeting psma antigen, and chelate and use thereof in diagnosis and treatment of prostate cancer |
| KR20240121775A (ko) * | 2021-11-26 | 2024-08-09 | 풀-라이프 테크놀로지스 에이치케이 리미티드 | 세포 표면 수용체를 표적화하는 절단 가능 방사성 리간드 및 이의 용도 |
| US20250186627A1 (en) * | 2022-03-04 | 2025-06-12 | Provincial Health Services Authority | Radiolabeled compounds targeting the prostate-specific membrane antigen |
| CN115010629B (zh) * | 2022-06-07 | 2024-02-23 | 西南医科大学附属医院 | 前列腺特异性膜抗原抑制剂、其核素标记物及制法和应用 |
| EP4583917A1 (en) * | 2022-09-07 | 2025-07-16 | 3B Pharmaceuticals GmbH | Prostate specific membrane antigen (psma) ligands and use thereof |
| TW202410923A (zh) * | 2022-09-09 | 2024-03-16 | 大陸商同宜醫藥（蘇州）有限公司 | 放射性核種偶聯藥物及其藥物組成物和應用 |
| TW202426433A (zh) | 2022-09-23 | 2024-07-01 | 瑞士商紐利迪姆股份公司 | 成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途 |
| AU2023347470A1 (en) * | 2022-09-23 | 2025-04-10 | Nuclidium Ag | High-purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof |
| EP4667019A1 (en) * | 2023-02-16 | 2025-12-24 | Norroy Bioscience Co., Ltd. | Psma-targeted radiopharmaceutical, and synthesis and use thereof |
| WO2024245407A1 (en) * | 2023-05-31 | 2024-12-05 | Full-Life Technologies Hk Limited | Conjugates and uses thereof |
| AU2024282578A1 (en) * | 2023-05-31 | 2025-12-04 | Full-Life Technologies Hk Limited | Radioligands for targeting cell surface receptors and uses thereof |
| WO2025029946A1 (en) | 2023-07-31 | 2025-02-06 | Curium Us Llc | [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof |
| WO2025088147A1 (en) * | 2023-10-27 | 2025-05-01 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Theranostic psma-targeting ligands for the diagnosis and treatment of psma-expressing cancers and their solid phase synthesis |
| WO2025218879A1 (en) | 2024-04-15 | 2025-10-23 | Itm Technologies Munich Se | Stable formulations comprising 225-actinium labeled complexes and methods for preparing the same |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0621973D0 (en) | 2006-11-03 | 2006-12-13 | Philogen Spa | Binding molecules and uses thereof |
| CA2819850C (en) * | 2010-12-06 | 2019-07-23 | John W. Babich | Psma-targeted dendrimers |
| HUE045028T2 (hu) | 2011-08-05 | 2019-12-30 | Molecular Insight Pharm Inc | Radiojelzett prosztataspecifikus membrán antigén inhibitorok |
| KR102036199B1 (ko) | 2011-08-17 | 2019-10-24 | 메르크 앤드 씨에 | 알부민-결합 개체들의 폴레이트 공액체들 |
| AU2014228233B2 (en) | 2013-03-15 | 2019-02-28 | Cancer Targeted Technology Llc | 18F-labeled PSMA-targeted pet imaging agents |
| EP2862857A1 (en) | 2013-10-18 | 2015-04-22 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| GEP20237497B (en) | 2013-10-18 | 2023-04-10 | Deutsches Krebsforsch | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| AU2017311510B2 (en) | 2016-08-10 | 2021-11-18 | Cancer Targeted Technology Llc | Chelated PSMA inhibitors |
-
2018
- 2018-05-24 US US16/616,744 patent/US11629201B2/en active Active
- 2018-05-24 CA CA3060143A patent/CA3060143A1/en active Pending
- 2018-05-24 CN CN201880034324.3A patent/CN110740757B/zh active Active
- 2018-05-24 KR KR1020197038065A patent/KR102843240B1/ko active Active
- 2018-05-24 EP EP18725856.1A patent/EP3630204A1/en active Pending
- 2018-05-24 AU AU2018274184A patent/AU2018274184B2/en active Active
- 2018-05-24 WO PCT/EP2018/063734 patent/WO2018215627A1/en not_active Ceased
- 2018-05-24 JP JP2019562312A patent/JP7340459B2/ja active Active
-
2019
- 2019-10-16 ZA ZA2019/06832A patent/ZA201906832B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN110740757B (zh) | 2023-04-04 |
| EP3630204A1 (en) | 2020-04-08 |
| RU2019141963A (ru) | 2021-06-24 |
| ZA201906832B (en) | 2024-02-28 |
| CA3060143A1 (en) | 2018-11-29 |
| RU2019141963A3 (enExample) | 2021-09-22 |
| KR20200009091A (ko) | 2020-01-29 |
| US20210009715A1 (en) | 2021-01-14 |
| WO2018215627A1 (en) | 2018-11-29 |
| AU2018274184A1 (en) | 2019-11-07 |
| JP2020520902A (ja) | 2020-07-16 |
| JP7340459B2 (ja) | 2023-09-07 |
| US11629201B2 (en) | 2023-04-18 |
| KR102843240B1 (ko) | 2025-08-05 |
| CN110740757A (zh) | 2020-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018274184B2 (en) | Novel PSMA-binding agents and uses thereof | |
| AU2019386997B2 (en) | Novel tumor antigen binding agents and uses thereof | |
| AU2018308699B2 (en) | Dual mode radiotracer and -therapeutics | |
| AU2014336638C1 (en) | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| JP7502801B2 (ja) | ガストリン放出ペプチド受容体（ｇｒｐｒ）のインビボイメージングおよびｇｒｐｒ関連障害の治療のための放射性標識ボンベシン由来化合物 | |
| HUP0401265A2 (hu) | Javított kelátképző vegyületek | |
| CA2969551A1 (en) | Bifunctional do2pa derivatives, chelates with metallic cations and use thereof | |
| JP2024505374A (ja) | デュアルモード放射性トレーサーおよびその療法 | |
| WO2018233798A1 (en) | Novel psma-binding agents and uses thereof | |
| WO2006094725A1 (en) | Chelators for radioactively labeled conjugates comprising a stabilizing sidechain | |
| RU2787105C2 (ru) | Новые пса-связывающие агенты и их применение | |
| RU2831681C2 (ru) | Новые связывающие опухолевый антиген агенты и их применение | |
| HK40054611A (en) | Novel tumor antigen binding agents and uses thereof | |
| WO2025171887A1 (en) | Radiolabeled complexes and pharmaceutical compositions including the same | |
| KR20240099330A (ko) | 위 억제 펩티드 수용체 리간드 | |
| WO2025160448A1 (en) | B7-h3 targeting peptides and constructs thereof | |
| CN121013861A (zh) | 具有生物分布调节剂的抑胃肽受体配体 | |
| JP2025525111A (ja) | 放射性医薬品のためのケイ素系フッ化物アクセプター基 | |
| JP2025509631A (ja) | セラノスティック薬剤の標的送達 | |
| Trencsényi et al. | Comparative preclinical evaluation of 68Ga-NODAGA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HB | Alteration of name in register |
Owner name: PAUL SCHERRER INSTITUT Free format text: FORMER NAME(S): ITM ISOTOPEN TECHNOLOGIEN MUENCHEN AG; PAUL SCHERRER INSTITUT Owner name: ITM ISOTOPE TECHNOLOGIES MUNICH SE Free format text: FORMER NAME(S): ITM ISOTOPEN TECHNOLOGIEN MUENCHEN AG; PAUL SCHERRER INSTITUT |
|
| FGA | Letters patent sealed or granted (standard patent) |